The following is a summary of “Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of ...

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

Ebdarokimab was evaluated in five clinical studies involving Chinese patients with moderate-to-severe plaque psoriasis. Two pivotal Phase III studies demonstrated ebdarokimab's efficacy and safety at ...